Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | NCEH1 | Q6PIU2 | 7/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3081463 | 0.81 | MAPT (0.58) | MAPTCYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL5610039 | 0.77 | MAPT (0.63) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL13323849 | 0.77 | MAPT (0.58) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL3251341 | 0.77 | ALDH1A1 (0.39) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL3274613 | 0.77 | MAPT (0.62) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL2119647 | 0.77 | ALOX5 (0.47) | MAPTKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL2814633 | 0.76 | IRAK4 (0.44) | MAPTCYP1A2CYP2C9CYP2C19IRAK4 | |
| SCHEMBL3242877 | 0.75 | NCEH1 (0.48) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL27740253 | 0.75 | MAPT (0.60) | MAPTCYP1A2CYP2C9CYP2C19NCEH1 | |
| SCHEMBL4877102 | 0.74 | GAA (0.51) | CYP2C9TLR8MCHR1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275095-A1 | Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases | ASTELLAS PHARMA INC. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1742662-A2 | COMBINATION OF PROSTAGLANDIN E2 RECEPTOR ANTAGONISTS AND RENIN-ANGIOTENSIN SYSTEM INHIBITORS FOR TREATING RENAL DISEASES | Astellas Pharma Inc. (JP) | 2007-01-17 | — | — | EP | disclosed |
| WO-2005105147-A2 | COMBINATION OF PROSTAGLANDIN E2 RECEPTOR ANTAGONISTS AND RENIN-ANGIOTENSIN SYSTEM INHIBITORS FOR TREATING RENAL DISEASES | ASTELLAS PHARMA INC. (JP) | 2005-11-10 | — | — | WO | disclosed |
| US-6437146-B1 | MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-08-20 | — | — | US | disclosed |
| EP-1115712-A1 | OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000018744-A1 | OXAZOLE COMPOUNDS AS PROSTAGLANDIN E2 AGONISTS OR ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999015524-A1 | THIAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275095-A1 | Combination of Prostaglandin E2 Receptor Antagonists and Renin-Angiotensin System Inhibitors for Treating Renal Diseases | AGTR2, REN, AGTR1 | MAPT 4280/4885CYP1A2 340/4885CYP2C9 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.